Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oxime Ether. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN105263902A reveals phosphate ester catalysis for oximes. Enhances yield and supply chain reliability for pharmaceutical intermediate production globally.
Patent CN114835660A reveals a metal-free, visible-light mediated method for oxime ether synthesis, offering high purity and cost reduction in pharmaceutical intermediate manufacturing.
Novel ketal-protection route for high-purity triketone derivatives. Reduces isomer separation costs for crop protection manufacturing.
Patent CN114394913A reveals a metal-free heteropoly acid catalytic route for oxime ether derivatives, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN120365187B reveals a one-pot Cu-TMEDA catalyzed method for oxime ether. This breakthrough offers significant cost reduction and supply chain reliability for fungicide manufacturing.
Patent CN111560044B reveals a novel synthesis for 11-O-mogrol oxime ethers. Discover enhanced solubility, antioxidant activity, and scalable manufacturing for functional additives.
Patent CN109280025A reveals a novel copper-catalyzed synthesis for high-purity oxime ether derivatives, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN121378334A reveals metal-free phosphonylation enabling high-purity unsaturated phosphate esters with reduced manufacturing costs and improved supply chain reliability for global buyers.
Patent CN110606813A reveals a novel oxime ether synthesis. Discover cost-effective manufacturing and high-purity supply chain solutions for fine chemical intermediates.
Patent CN114394913B introduces a metal-free heteropolyacid catalyzed synthesis of oxime ethers. This method offers significant cost reduction and environmental benefits for pharmaceutical intermediate manufacturing.
Patent CN112279779B details a mild copper-catalyzed asymmetric oxime etherification. Discover high-ee pharmaceutical intermediates and cost-effective manufacturing solutions.
Patent CN110698393A discloses a metal-free radical relay method using fluorinated oxime ethers for efficient drug intermediate synthesis, offering significant cost reduction and supply chain reliability.
Patent CN112500311A reveals a novel benzophenone-mediated synthesis for O-3-chloro-2-propenyl hydroxylamine, offering >98% purity and recyclable reagents for clethodim production.